Hexafluorenium bromide - CAS 317-52-2
Catalog number: 317-52-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C36H42N2.2Br
Molecular Weight:
662.54008
COA:
Inquire
Targets:
Others
Description:
Hexafluronium bromide is .a cholinesterase inhibitor used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery
Purity:
≥98%
Appearance:
Solid powder
Synonyms:
Mylaxen; 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium;dibromide;
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Acetylcholine Receptor
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
InChIKey:
WDEFPRUEZRUYNW-UHFFFAOYSA-L
InChI:
1S/C36H42N2.2BrH/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36;;/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3;2*1H/q+2;;/p-2
Canonical SMILES:
C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-]
1.Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats.
Koller ME, Breivik H, Greider P, Jones DJ, Smith RB. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
The effects of spinal cord transection and acidosis on succinylcholine (SCC)-induced hyperkalemia were studied in Sprague-Dawley rats. The effectiveness of pretreatment with subparalyzing doses ("self-taming") of SCC or with the cholinesterase inhibitor hexafluorenium bromide in preventing hyperkalemia was also studied. The increase in plasma potassium after administration of SCC (1 mg/kg) was found to be significantly increased 10 days after spinal cord transection. This potassium increase could not be prevented by pretreatment with either hexafluorenium (0.3 mg/kg) or subparalyzing doses (0.15 mg/kg) of SCC. Respiratory acidosis caused an increase in plasma K+ in both normal and in spinal cord transected rats. Acidosis had a synergistic effect on succinylcholine-induced hyperkalemia. These findings support the clinical practice of not using succinylcholine in patients at risk of having a pathological sensitivity to SCC. Furthermore, SCC may be especially dangerous when administered to patients who are acidotic.
2.In vivo reversal of depolarizing neuromuscular blockade.
Riker WF Jr1, Okamoto M, Artusio JF Jr. Arch Int Pharmacodyn Ther. 1995 Jul-Aug;330(1):90-101.
The antagonism of depolarizing blockers, principally succinylcholine and decamethonium, by tetraethyl- and tetrabutylammonium ions in an in vivo neuromuscular preparation in anesthetized cats is described; possible mechanisms for these effects are discussed. Tetraethyl- (50-100 mg/kg, i.v.) and tetrabutylammonium (1-5 mg/kg, i.v.) produced sharp reversals of 95-99% succinylcholine and decamethonium blocks. These reversals were effective and sustained at any point during the course of the blockades. Tetraethyl- or tetrabutylammonium, administered 2-3 min before succinylcholine or decamethonium, prevented blockade, an effect compatible with an earlier reported in vitro investigation. The studies of others disclose the interaction of depolarizing blockers with acetylcholine receptors, leading to channel opening, channel entry and binding therein of these blockers. The present studies support this in showing the prevention of succinylcholine and decamethonium block by the prior administration of tetraethylammonium, which also interacts with acetylcholine receptors.
3.Characterization of end-plate conductance in transected frog muscle: modification by drugs.
Lambert JJ, Durant NN, Reynolds LS, Volle RL, Henderson EG. J Pharmacol Exp Ther. 1981 Jan;216(1):62-9.
Cutaneous pectoris muscles of Rana pipiens were transected distal to the innervated region. Within 10 min, membrane potentials (Em's) of -33 +/- 2.5 mV and end-plate potentials (3-15 mV) were recorded unaccompanied by muscle action potentials or twitch. The fall in Em was associated with a net loss of [K+]i and a net gain of [Na+]i. Although input resistance fell by 50% and the space constant was slightly reduced in the transected muscle fibers, end-plates could be adequately voltage-clamped with two microelectrodes. End-plate currents (e.p.c.s) with rise times of 350 to 700 musec were recorded as a function of holding potential (Vm). The current-voltage relationship of peak e.p.c.s over the range of -70 to +20 mV was linear and the reversal potential (-6.6 +/- 2.2 mV) was the same as that found for intact muscle fibers. The decay phase of e.p.c.s could be described as a single exponential at all Vm's and had a voltage and temperature dependence similar to that described for e.
4.Bile salts and neuromuscular blocking agents.
Westra P, Houwertjes MC, Wesseling H, Meijer DK. Br J Anaesth. 1981 Apr;53(4):407-15.
The influence of the primary bile salts taurocholate and chenodeoxycholate on the neuromuscular blockade of the non-depolarizing drugs Org 6368, pancuronium, Org NC 45 and hexafluorenium was studied in cats. An increase in the effects of these agents, all possessing widely varying molecular structures, was found following administration of the bile salts. The bile salt concentrations in plasma were similar to those obtained after 9-10 days of extrahepatic cholestasis in cats. The effect of Org NC 45, a new monoquaternary analogue of pancuronium, was increased more than that of pancuronium. This increase in effect is probably a result of inhibition of the hepatic uptake of the neuromuscular blocking drugs. The neuromuscular blocking effect of gallamine was not influenced significantly by the administration of bile salts.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 968-81-0 Acetohexamide

Acetohexamide
(CAS: 968-81-0)

Acetohexamide, a sulfonylurea derivative, is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose dia...

CAS 57-09-0 Cetrimonium Bromide

Cetrimonium Bromide
(CAS: 57-09-0)

Cetrimonium Bromide is a known component of the broad-spectrum antiseptic cetrimide, which is a mixture of different quaternary ammonium salts.

CAS 51014-29-0 Isocorynoxeine

Isocorynoxeine
(CAS: 51014-29-0)

Isocorynoxeine is a alkaloid extracted from Uncaria Hook shows the effects of lowering blood pressure.

LY 164929
(CAS: 113573-18-5)

This active molecular is a highly selective ligand for the lower affinity [3H]D-Ala2-D-Leu-5-enkephalin binding site.

CAS 1922099-21-5 CCG 232601

CCG 232601
(CAS: 1922099-21-5)

CCG 232601 is a selective and orally bioactive inhibitor of the Rho/MRTF/SRF signaling pathway (IC50 value of 0.55 μM (SRE.L assay)) as a potential antifibrotic...

CAS 520505-01-5 NCS-382

NCS-382
(CAS: 520505-01-5)

NCS-382 is a γ-Hydroxybutyric acid antagonist as an anticonvulsant.

Lanopepden
(CAS: 1152107-25-9)

This active molecular is a selective peptide deformylase inhibitor. It has good anti-bacteria activity in vitro. Antibacterial spectrum of Lanopepden includes S...

CAS 130-86-9 Protopine

Protopine
(CAS: 130-86-9)

Protopine, an isoquinoline alkaloid compound, is a Ca2+ channel blocker and could be used in immunoregulation.

CAS 1401089-31-3 PACMA 31

PACMA 31
(CAS: 1401089-31-3)

PACMA 31 is a protein disulfide isomerase family inhibitor as promising target for chemotherapy. It inhibits growth of ovarian cancer cells.

CAS 1256094-72-0 AI-10-49

AI-10-49
(CAS: 1256094-72-0)

AI-10-49 is a protein-protein interaction inhibitor that selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1 with a FRET IC50 of 0.26 uM.

CAS 39959-66-5 LY 78335

LY 78335
(CAS: 39959-66-5)

LY 78335 is a phenylethanolamine N-methyl transferase (PNMT) inhibitor.

CAS 432001-69-9 Skp2 Inhibitor C1

Skp2 Inhibitor C1
(CAS: 432001-69-9)

Skp2 Inhibitor C1(SKPin C1) is a specific small molecule inhibitor of Skp2-mediated p27 degradation, selectively inhibits Skp2-mediated p27 degradation by reduc...

CAS 25487-28-9 Talsupram hydrochloride

Talsupram hydrochloride
(CAS: 25487-28-9)

Talsupram hydrochloride is a selective noradrenalin reuptake (SLC6A2) inhibitor, displaying high affinity for the human noradrenalin transporter (NET) against S...

Cgp 13143
(CAS: 75919-69-6)

Cgp 13143 is a bio-active chemical,but no detailed information has been published yet.

CAS 2156-56-1 DCA

DCA
(CAS: 2156-56-1)

DCA is a mitochondrial pyruvate dehydrogenase kinase (PDK) inhibitor that shifts pyruvate metabolism from glycolysis and lactate production to glucose oxidation...

Cgp 21833
(CAS: 122378-49-8)

Cgp 21833 has a thiocarbonylamides structure and it is a potent antifilarial agent under laboratory research stage.

JNJ7925476 HCl
(CAS: 109085-56-5)

JNJ7925476 HCl is a novel triple monoamine uptake inhibitor. It blocks the serotonin transporter (SERT), norepinephrine transporter (NET) and dopamine transport...

SR9011
(CAS: 1379686-29-9)

SR9011, a synthetic REV-ERB agonist, has been found to have probable effect against sleep disorders and metabolic diseases. IC50: 790 nM and 560 nM for Rev-ErbB...

CAS 2809-21-4 Etidronic acid

Etidronic acid
(CAS: 2809-21-4)

Etidronate (Didronel) is a human protein tyrosine phosphatase inhibitor with IC50 of 0.2 μM.

CP-467688
(CAS: 208590-81-2)

CP-467688 is a microsomal triglyceride transfer protein inhibitor used in atherosclerosis therapy.

Chemical Structure

CAS 317-52-2 Hexafluorenium bromide

Quick Inquiry

Verification code

Featured Items